Daniel P. Van Plew - Feb 9, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP & General Mgr, Industrial
Signature
/s/**Daniel P. Van Plew
Stock symbol
REGN
Transactions as of
Feb 9, 2024
Transactions value $
-$10,353,341
Form type
4
Date filed
2/13/2024, 04:04 PM
Previous filing
Dec 12, 2023
Next filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock +Options Exercise $4,562,635 +12,250 +60.11% $372.46 32,628 Feb 9, 2024 Direct
transaction REGN Common Stock -Tax liability -$8,184,448 -8,600 -26.36% $951.68 24,028 Feb 9, 2024 Direct
transaction REGN Common Stock +Options Exercise $8,819,875 +23,125 +96.24% $381.40 47,153 Feb 9, 2024 Direct
transaction REGN Common Stock -Tax liability -$15,551,403 -16,341 -34.66% $951.68 30,812 Feb 9, 2024 Direct
holding REGN Common Stock 12,376 Feb 9, 2024 2023 GRAT
holding REGN Common Stock 1,084 Feb 9, 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) -Options Exercise $0 -12,250 -50% $0.00 12,250 Feb 9, 2024 Common Stock 12,250 $372.46 Direct F1
transaction REGN Non-Qualified Stock Option (right to buy) -Options Exercise $0 -23,125 -100% $0.00 0 Feb 9, 2024 Common Stock 23,125 $381.40 Direct F1

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.